Prednizon etkileşimleri

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (Abirateron etiketi, Uyarılar ve önlemler)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Adalimumab etiketi, Kutulu uyarı)

…Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (Adrenalin etiketi, İlaç etkileşimleri)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (Aksitinib etiketi, Uyarılar ve önlemler)

Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (Arformoterol etiketi, Kontrendikasyonlar)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (Arsenik trioksit etiketi, Kutulu uyarı)

Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (Atazanavir etiketi, İlaç etkileşimleri)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Barisitinib etiketi, Kutulu uyarı)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Dosetaksel etiketi, Uyarılar ve önlemler)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (Emtrisitabin, rilpivirin ve tenofovir etiketi, Kontrendikasyonlar)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Etanersept etiketi, Kutulu uyarı)

Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (Formoterol etiketi, Kontrendikasyonlar)

Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (Fosamprenavir etiketi, İlaç etkileşimleri)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (İnfliksimab etiketi, Kutulu uyarı)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (Ketokonazol etiketi, İlaç etkileşimleri)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (Lovastatin etiketi, Kontrendikasyonlar)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (Mifepriston etiketi, Kutulu uyarı)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (Mitotan etiketi, Kutulu uyarı)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (Moeksipril etiketi, Uyarılar)

Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (Nevirapin etiketi, Uyarılar ve önlemler)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (Rilpivirin etiketi, Kontrendikasyonlar)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Salmeterol etiketi, Kutulu uyarı)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (Sirolimus etiketi, Uyarılar ve önlemler)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin etiketi, İlaç etkileşimleri)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Tofasitinib etiketi, Kutulu uyarı)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Tosilizumab etiketi, Kutulu uyarı)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (Trandolapril etiketi, Uyarılar)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin etiketi, Kutulu uyarı)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (Umeklidinyum ve vilanterol etiketi, Kontrendikasyonlar)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Upadasitinib etiketi, Kutulu uyarı)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Afatinib etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Aklidinyum etiketi, İlaç etkileşimleri)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (Albendazol etiketi, Uyarılar ve önlemler)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (Alemtuzumab etiketi, Uyarılar ve önlemler)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (Alendronat etiketi, Uyarılar ve önlemler)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (Aliskiren etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (Alpelisib etiketi, Uyarılar ve önlemler)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (Amfoterisin B etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. (Azatioprin etiketi, Uyarılar)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Hypercorticism and Adrenal Suppression QVAR REDIHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (Beklometazon etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Belladonna ve afyon etiketi, Uyarılar ve önlemler)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (Benralizumab etiketi, Uyarılar ve önlemler)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with PULMICORT FLEXHALER. (Budesonid etiketi, Uyarılar ve önlemler)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin ve nalokson etiketi, Uyarılar ve önlemler)

…risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (Bupropion etiketi, Uyarılar ve önlemler)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Butorfanol etiketi, Uyarılar)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (Daptomisin etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Denosumab etiketi, Uyarılar ve önlemler)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Digitalis Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (Disikloverin etiketi, İlaç etkileşimleri)

…treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (Doksorubisin etiketi, İlaç etkileşimleri)

…following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (Dolutegravir etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (Dupilumab etiketi, Uyarılar ve önlemler)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Erlotinib etiketi, Uyarılar ve önlemler)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (Fenilefrin etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fentanil etiketi, Uyarılar ve önlemler)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (Fingolimod etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

The use of flunisolide with alternate-day prednisone systemic treatment could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. (Flunisolid etiketi, Uyarılar)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (Fluosinonid etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with Fluticasone Propionate DISKUS. (Flutikazon etiketi, Uyarılar ve önlemler)

Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (Flutikazon ve salmeterol etiketi, Uyarılar ve önlemler)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Gliserol fenilbütirat etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (Halobetazol etiketi, Uyarılar ve önlemler)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (Hidralazin etiketi, Uyarılar)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon ve homatropin etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon ve klorfeniramin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidrokodon ve parasetamol etiketi, Uyarılar)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Hidromorfon etiketi, Uyarılar ve önlemler)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (İbandronat etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (İvermektin etiketi, Uyarılar)

Antitubercular Drugs Serum concentrations of isoniazid may be decreased. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (Kladribin etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Kodein etiketi, Uyarılar ve önlemler)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (Kokain etiketi, İlaç etkileşimleri)

Cholestyramine Cholestyramine may increase the clearance of corticosteroids. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Levofloksasin etiketi, Uyarılar ve önlemler)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Levorfanol etiketi, Uyarılar)

If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Levosalbutamol etiketi, Uyarılar ve önlemler)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (Prednizon etiketi, Uyarılar ve önlemler)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (Prednizon etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (Lisinopril ve hidroklorotiyazid etiketi, Uyarılar)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (Prednizon etiketi, Uyarılar ve önlemler)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (Margetuksimab etiketi, Uyarılar ve önlemler)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Decrease corticosteroids gradually, if appropriate. (Mepolizumab etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Metadon etiketi, Uyarılar ve önlemler)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (Metazolamid etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (Prednizon etiketi, Uyarılar ve önlemler)

This can be corrected by giving appropriate doses of corticosteroids. (Metirapon etiketi, Uyarılar ve önlemler)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (Prednizon etiketi, İlaç etkileşimleri)

Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (Metolazon etiketi, İlaç etkileşimleri)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (Metotreksat etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (Mitoksantron etiketi, Uyarılar)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Moksifloksasin etiketi, Uyarılar ve önlemler)

Hypercorticism and Adrenal Suppression ASMANEX HFA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (Mometazon etiketi, Uyarılar ve önlemler)

Inhaled corticosteroid may be reduced gradually. (Montelukast etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Morfin etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Nalbufin etiketi, Uyarılar)

…hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (Naltrekson ve bupropion etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (Natalizumab etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Nintedanib etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Ofloksasin etiketi, Uyarılar)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (Okrelizumab etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oksikodon etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oksikodon ve parasetamol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oksimorfon etiketi, Uyarılar ve önlemler)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Oliseridin etiketi, Uyarılar ve önlemler)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronat etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Parasetamol ve kodein etiketi, Uyarılar)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (Pasireotid etiketi, Uyarılar ve önlemler)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Penisilamin etiketi, Uyarılar)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Pentazosin ve nalokson etiketi, Uyarılar)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Petidin etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (Ponesimod etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (Prednizon etiketi, Uyarılar ve önlemler)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (Prednizon etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Prometazin ve kodein etiketi, Uyarılar ve önlemler)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (Prednizon etiketi, Uyarılar ve önlemler)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (Propofol etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (Risedronat etiketi, Uyarılar ve önlemler)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (Rokuronyum etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Salbutamol etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (Sefoksitin etiketi, Uyarılar ve önlemler)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during ALVESCO therapy [see Dosage and Administration ( 2 )] . (Siklesonid etiketi, Uyarılar ve önlemler)

Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Siprofloksasin etiketi, Uyarılar ve önlemler)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (Sitarabin etiketi, İlaç etkileşimleri)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (Sodyum fenilbütirat etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Süksinilkolin etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (Takrolimus etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Tapentadol etiketi, Uyarılar ve önlemler)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Temozolomid etiketi, Uyarılar ve önlemler)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus etiketi, Uyarılar ve önlemler)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (Teofilin etiketi, Uyarılar)

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (Prednizon etiketi, Uyarılar ve önlemler)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (Testosteron etiketi, Uyarılar ve önlemler)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Tiotropium etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (Prednizon etiketi, İlaç etkileşimleri)

Corticosteroids and ACTH: Increased risk of hypokalemia. (Torasemid etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Tramadol etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Tramadol ve parasetamol etiketi, Uyarılar ve önlemler)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Trastuzumab etiketi, Uyarılar ve önlemler)

Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (Triamteren ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (Valproik asit etiketi, İlaç etkileşimleri)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (Zenokutuzumab etiketi, Uyarılar ve önlemler)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (Zoledronik asit etiketi, Uyarılar ve önlemler)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplaz etiketi, Uyarılar ve önlemler)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Amfetamin etiketi, İlaç etkileşimleri)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Amfetamin ve dekstroamfetamin etiketi, İlaç etkileşimleri)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (Amikasin etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Ampisilin etiketi, Uyarılar)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (Bempedoik asit etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (Bevasizumab etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

…50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (Bortezomib etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Busulfan etiketi, Uyarılar)

Prednizon gibi kortikosteroidler kalsiyum emilimini azaltır ve D vitamini metabolizmasını bozarak kemik kaybına katkıda bulunur. (NIH Office of Dietary Supplements, Vitamin D)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (Droperidol etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

Steroids may or may not be effective in controlling these hemolytic episodes. (Fludarabin etiketi, Uyarılar ve önlemler)

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (Prednizon etiketi, Uyarılar ve önlemler)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (Fluoksetin etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (Guselkumab etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Amphotericin B Injection There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure [see Drug Interactions (7.14) ] . (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (İpratropium etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (Kalsitriol etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (Kannabidiol (reçeteli) etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (Kinin etiketi, İlaç etkileşimleri)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (Klofarabin etiketi, Uyarılar ve önlemler)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (Klomifen etiketi, Uyarılar)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (Kortikotropin etiketi, Uyarılar ve önlemler)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Lenalidomid etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (Melfalan etiketi, Uyarılar)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Metamfetamin etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (Midodrin etiketi, İlaç etkileşimleri)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

Moderate and weak CYP3A4 inducers include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirnenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib. (Nimodipin etiketi, İlaç etkileşimleri)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (Oksasilin etiketi, Uyarılar)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (Penisilin G etiketi, Uyarılar)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Penisilin V etiketi, Uyarılar)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (Pilokarpin etiketi, İlaç etkileşimleri)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (Raloksifen etiketi, İlaç etkileşimleri)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (Rituksimab etiketi, Uyarılar ve önlemler)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefadroksil etiketi, Uyarılar ve önlemler)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefaklor etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefdinir etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefotetan etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Sefprozil etiketi, Uyarılar)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Seftazidim etiketi, Uyarılar)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (Seftriakson etiketi, Uyarılar ve önlemler)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (Sodyum zirkonyum siklosilikat etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (Tenekteplaz etiketi, Uyarılar ve önlemler)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (Tobramisin etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (Ustekinumab etiketi, Uyarılar ve önlemler)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (Ziprasidon etiketi, Uyarılar ve önlemler)

…influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline… (Aminofilin etiketi, İlaç etkileşimleri)

Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (Zileuton etiketi, İlaç etkileşimleri)